An interventional study of Dexmedetomidine in Brain Tumor and Cerebrovascular Disorders, sponsored by National Taiwan University Hospital. Completed at 1 site in Taiwan. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2020-09-22.
Sponsored by National Taiwan University Hospital · Not applicable, Interventional, and Treatment
Dexmedetomidine (DEX) is a Alpha-2 specific agonist, is a common ICU sedation medication. In brain tumor resection craniotomy, it is proven to be effective in improving postoperative hypertension and tachycardia, mitigates postoperative nausea and vomiting and relives postoperative pain. In addition, many animal experiments show that DEX inhibits the proapoptosis in the mitochondrial in vivo and therefore avoids neuronal injury. It is also reported to be neuroprotective to isoflurane-induced neurotoxicity and to improve cerebral focal ischemic region (penumbra). However, the neuroprotective effects were never investigated clinically in patients undergoing brain tumor resection surgery.
374 studies on the registry are indexed under Cerebrovascular Disorders; 129 are open to participants now.
This study's enrollment of 160 is above the median of 110 across 214 interventional studies indexed under Cerebrovascular Disorders.
Browse Cerebrovascular Disorders studies →National Taiwan University Hospital is the lead sponsor of 2,563 studies on the registry; 569 are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 2 (18%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Intraoperative intravenous infusion of dexmedetomidine
Drug: Dexmedetomidine
Intraoperative intravenous infusion of 0.9% saline
Drug: Dexmedetomidine
Intraoperative dexmedetomidine infusion
Number of participants with postoperative neurological complications
Time frame: during postoperative period of hospital admission, approximately 10 days by estimation
Number of participants with postoperative delirium
Time frame: during postoperative period of hospital admission, approximately 10 days by estimation
Serum biomarkers changes
biomarkers related to neuroinflammation and neuronal injury, such as HMGB1 and GFAP
Time frame: Between preoperative baseline and postoperative day one.
Intraoperative haemodynamic profile
Time frame: during intraoperative perioid, approximately 4-6 hours by estimation
This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Taiwan University Hospital